Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK.

[1]  H. Ceulemans,et al.  Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. , 2015, Journal of hepatology.

[2]  Richard H. Liang,et al.  Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. , 2015, The Journal of infectious diseases.

[3]  C. Sarrazin,et al.  Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. , 2015, Antiviral research.

[4]  Tara L. Kieffer,et al.  Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study. , 2014, The Journal of infectious diseases.

[5]  A. Molla,et al.  In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450 , 2014, Antimicrobial Agents and Chemotherapy.

[6]  Brian L. Pearlman,et al.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.

[7]  G. Duverlie,et al.  Patients eligible for treatment with simeprevir in a French center. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[8]  Cassandra B. Jabara,et al.  Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection , 2014, Antimicrobial Agents and Chemotherapy.

[9]  Oliver Lenz,et al.  Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial , 2014, The Lancet.

[10]  M. Manns,et al.  Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial , 2014, The Lancet.

[11]  Yoshiyuki Suzuki,et al.  Evolution of simeprevir‐resistant variants over time by ultra‐deep sequencing in HCV genotype 1b , 2014, Journal of medical virology.

[12]  X. Forns,et al.  Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. , 2014, Gastroenterology.

[13]  G. Kukolj,et al.  Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir , 2013, Antimicrobial Agents and Chemotherapy.

[14]  G. Wilkie,et al.  Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Côte d’Ivoire , 2013, AIDS.

[15]  Tara L. Kieffer,et al.  Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment , 2012, Journal of Virology.

[16]  Stefano Alcaro,et al.  HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors , 2012, PloS one.

[17]  Gkikas Magiorkinis,et al.  Assessment of phylogenetic sensitivity for reconstructing HIV-1 epidemiological relationships. , 2012, Virus research.

[18]  Chaoqun Chen,et al.  Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir , 2012, Antimicrobial Agents and Chemotherapy.

[19]  M. Zazzi,et al.  Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. , 2012, The Journal of antimicrobial chemotherapy.

[20]  R. Striker,et al.  Evidence for separation of HCV subtype 1a into two distinct clades , 2011, Journal of viral hepatitis.

[21]  Jun Yong Choi,et al.  Detection of Minority Resistance during Early HIV-1 Infection: Natural Variation and Spurious Detection rather than Transmission and Evolution of Multiple Viral Variants , 2011, Journal of Virology.

[22]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[23]  H. Mo,et al.  Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors , 2010, Antimicrobial Agents and Chemotherapy.

[24]  L. Vrang,et al.  In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435 , 2010, Antimicrobial Agents and Chemotherapy.

[25]  O. Gascuel,et al.  New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. , 2010, Systematic biology.

[26]  Paramvir S. Dehal,et al.  FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments , 2010, PloS one.

[27]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[28]  Jeroen Aerssens,et al.  VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering , 2015, Bioinform..